IMUNON Eliminates Headcount Not Essential To Phase 3 Trial
Benzinga Newsdesk 9 months ago
News
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 StudyKhursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the companyPhase 3 Study
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study
Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company
Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing